William John Sibold - Aug 21, 2025 Form 4 Insider Report for MADRIGAL PHARMACEUTICALS, INC. (MDGL)

Role
President and CEO, Director
Signature
/s/ Mardi Dier, as Attorney-in-Fact
Stock symbol
MDGL
Transactions as of
Aug 21, 2025
Transactions value $
-$3,047,756
Form type
4
Date filed
8/21/2025, 05:44 PM
Previous filing
Mar 7, 2025
Next filing
Sep 9, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Sibold William John President and CEO, Director C/O MADRIGAL PHARMACEUTICALS, INC., 200 BARR HARBOR DRIVE, SUITE 200, WEST CONSHOHOCKEN /s/ Mardi Dier, as Attorney-in-Fact 2025-08-21 0001518611

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MDGL Common Stock Sale -$2.59M -6.49K -5.53% $400.03 111K Aug 21, 2025 Direct F1, F2
transaction MDGL Common Stock Sale -$454K -1.13K -1.02% $401.00 110K Aug 21, 2025 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 These sales were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $400.00 to $400.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnote below.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $401.00 to $401.01, inclusive.